舒泰神(300204.SZ):公司堅持創新藥物研發,近期個別項目取得了一定的進展
格隆匯6月16日丨舒泰神(300204.SZ)在互動平台表示,2024年度,公司受外部環境及行業政策等因素影響,主要產品的銷售收入有所下降,報吿期內實現銷售收入3.25億元。同時,基於未來研發項目整體佈局和公司發展戰略考慮,公司多個在研項目所對應的多項適應症在持續推進臨牀試驗中;公司研發管線中有部分臨牀前在研項目持續推進;未來一定時間內,因公司在研項目持續推進的需求,預計仍將保持適當的研發投入水平。在未來的研發系統發展戰略中,公司仍然會圍繞所定位的治療領域,在國內研發環境日趨激烈和完善的情況下,聚焦臨牀階段特別是成藥性趨勢明顯的重點項目,加速產品的臨牀研究、產業化和學術市場化的進程。多年以來,公司堅持創新藥物研發,近期個別項目取得了一定的進展,包括注射用STSP-0601、STSA-1002注射液和BDB-001,相關進展可查閲相應項目進展公吿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.